Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
RCUS Arcus Biosciences Inc
- Stocks
- Healthcare
- NYSE: RCUS
Price (delayed)
$8.53
Market cap
$903.2M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$4.19
Enterprise value
$759.2M
Arcus Biosciences is an oncology-focused biopharmaceutical company leveraging its deep cross-disciplinary expertise to discover highly differentiated therapies and to develop a broad portfolio of novel combinations addressing significant unmet needs.
Highlights
RCUS's quick ratio is up by 19% since the previous quarter and by 4.4% year-on-year
RCUS's equity is down by 25% year-on-year but it is up by 9% since the previous quarter
The net income has dropped by 69% year-on-year and by 38% since the previous quarter
The gross profit has contracted by 45% from the previous quarter and by 41% YoY
Key stats
What are the main financial stats of RCUS
Market
Valuations
Earnings
Shares outstanding
105.89M
Market cap
$903.2M
Enterprise value
$759.2M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.7
Price to sales (P/S)
5.95
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.38
Revenue
$141M
Gross profit
$141M
Operating income
-$436M
Net income
-$391M
EBIT
-$386M
EBITDA
-$369M
Free cash flow
-$303M
Per share
Balance sheet
Liquidity
EPS
-$4.19
EPS diluted
-$4.19
Free cash flow per share
-$3.08
Book value per share
$5.02
Revenue per share
$1.43
TBVPS
$11.75
Total assets
$1.16B
Total liabilities
$625M
Debt
$48M
Equity
$531M
Working capital
$839M
Debt to equity
0.09
Current ratio
5.37
Quick ratio
5.27
Net debt/EBITDA
0.39
Margins
Efficiency
Dividend
EBITDA margin
-261.7%
Gross margin
100%
Net margin
-277.3%
Operating margin
-309.2%
Return on assets
-33%
Return on equity
-70.6%
Return on invested capital
-46%
Return on capital employed
-40%
Return on sales
-273.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
RCUS stock price
How has the Arcus Biosciences stock price performed over time
Intraday
6.49%
1 week
-1.04%
1 month
21.16%
1 year
-44.1%
YTD
-42.71%
QTD
8.66%
Financial performance
How have Arcus Biosciences's revenue and profit performed over time
Revenue
$141M
Gross profit
$141M
Operating income
-$436M
Net income
-$391M
Gross margin
100%
Net margin
-277.3%
Arcus Biosciences's net margin has plunged by 184% YoY and by 153% from the previous quarter
The operating margin has dropped by 171% year-on-year and by 142% since the previous quarter
The net income has dropped by 69% year-on-year and by 38% since the previous quarter
Arcus Biosciences's operating income has plunged by 61% YoY and by 32% from the previous quarter
Price vs fundamentals
How does RCUS's price correlate with its fundamentals
Growth
What is Arcus Biosciences's growth rate over time
Valuation
What is Arcus Biosciences stock price valuation
P/E
N/A
P/B
1.7
P/S
5.95
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.38
RCUS's EPS is down by 35% year-on-year and by 33% since the previous quarter
RCUS's price to book (P/B) is 37% lower than its 5-year quarterly average of 2.7 and 26% lower than its last 4 quarters average of 2.3
RCUS's equity is down by 25% year-on-year but it is up by 9% since the previous quarter
RCUS's P/S is 64% below its 5-year quarterly average of 16.4 but 10% above its last 4 quarters average of 5.4
RCUS's revenue is down by 45% QoQ and by 41% YoY
Efficiency
How efficient is Arcus Biosciences business performance
RCUS's return on sales has dropped by 189% year-on-year and by 154% since the previous quarter
The return on equity has dropped by 72% year-on-year and by 49% since the previous quarter
Arcus Biosciences's return on assets has shrunk by 71% YoY and by 42% QoQ
RCUS's ROIC has plunged by 69% YoY and by 42% from the previous quarter
Dividends
What is RCUS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for RCUS.
Financial health
How did Arcus Biosciences financials performed over time
The total assets is 85% greater than the total liabilities
RCUS's current ratio is up by 19% from the previous quarter and by 2.9% YoY
RCUS's quick ratio is up by 19% since the previous quarter and by 4.4% year-on-year
Arcus Biosciences's debt is 91% less than its equity
RCUS's equity is down by 25% year-on-year but it is up by 9% since the previous quarter
RCUS's debt to equity is down by 10% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.